By enabling the delivery of novel regenerative medicine therapies, our technologies are pushing the boundaries of possibility in these healthcare sectors:
Octane is advancing cell therapy with sophisticated bioreactor technology and cell culture automation. With our Octane Cocoon™ platform, the entire process of cell production occurs in a controlled, dynamic environment to ensure correct cell behaviour. Critical biological parameters, such as cell number, viability and phenotype are closely monitored and controlled to meet demanding release criteria.
Consistent with the growth of biologics and stem cell programs, Octane is pursuing targeted applications for clinical adoption of our Octane Cocoon platform. We are actively seeking partners who require innovation to achieve clinical targets for cell therapy. In addition to our cell culture automation, advanced biomaterials and tissue engineering technologies, we have the production systems and corporate drive to advance your scale-up and market delivery.
We’ve got the expertise and resources to deliver sophisticated technology platforms for automated tissue engineering. Over the last three decades, Octane has established a network of local and international collaborators who are recognized for their work in advanced biomaterials and tissue engineering. Combined with our own team of experts, this adds up to a diverse skill base in the highly specialized fields of biology, biomaterials and bioengineering – all critical to the development of clinical products for regenerative medicine therapies.
Changing demographics – defined increasingly by an aging population – are intensifying demand for orthopedic biomaterials with unconstrained lifetimes. Octane is meeting this demand with bioactive implants engineered to be remodeled by normal cell mechanisms, enabling the implant to be replaced over time by natural tissue. The result, ultimately, is complete healing – as if the injury never happened.
Recognizing that clinical superiority is critical to product success, Octane works closely with physicians at the earliest stages of concept development in regenerative orthopedics. Together, we establish and evaluate design criteria based on patient requirements, surgical practice, regulatory requirements and reimbursement. For our commercial partners, this ensures greater clinical acceptance and market performance.